Advertisement

GlaxoSmithKline Merger

  • B. Rajesh Kumar
Chapter
Part of the Management for Professionals book series (MANAGPROF)

Abstract

All the major pharma companies in the world have grown through mergers and acquisitions. The antecedents of GlaxoSmithKline include Glaxo, Wellcome, SmithKline French, and Beecham. Glaxo and Wellcome had merged to create synergies in research and development. The merger of Beecham and SmithKline in the year 1989 sparked a wave of mergers between pharmaceutical mergers in the next decade. Glaxo Wellcome group was formed due to the merger between Glaxo and Burroughs Wellcome & Company. The merger between Glaxo Wellcome and SmithKline created the world’s largest pharmaceutical company, and the combined company became the third largest corporation in the world. The merger resulted in economies of scale, complementary portfolios, operational synergies, and cost savings. Glaxo Wellcome shareholders received approximately 58.75% of the issued ordinary share capital of GlaxoSmithKline, and SmithKline Beecham shareholders received approximately 41.25% of the issued ordinary share capital of GlaxoSmithKline. The merger helped the combined firm to achieve economies of scale in the pharmaceutical sector. GlaxoSmithKline Beecham (GSK) became the largest pharmaceutical company in the world. GSK became the world’s largest producer of prescription drugs with market share of more than 7%. The merger also facilitated avoidance of increased R&D costs. The merger enhanced the complementary portfolio of the two pharmaceutical companies. The combination of Glaxo Wellcome’s respiratory therapeutic segment with SmithKline Beecham’s strength in vaccines and arthritis broadened the portfolio of offerings. The cumulative returns for GSK during the 251 days’ merger window period (−10 to 240 days) were 8.93%.

References

  1. Danzon PM, Epstein A, Nicholson S (2003) Mergers and acquisitions in the pharmaceutical and biotech industries. Organizational economics of health care conference, p 43Google Scholar
  2. GSK Website Accessed 01 Nov 2017Google Scholar
  3. Lazo BB (2001) GSK a case study on the strategy of merger of equals in ethical pharmaceuticals. http://econwpa.repec.org/eps/io/papers/0211/0211017.pdf. Accessed 01 Nov 2017
  4. M&A Monitor Ltd. UK 2002. http://www.m-a-monitor.com/xam-bin/m?mah01894. Accessed 01 Nov 2017
  5. New York Times (1989) SmithKline Beecham to Merge. www.nytimes.com/1989/.../smithkline-beecham-to-merge.html. Accessed 01 Nov 2017
  6. Pharmaceutical Online (2000) Glaxo Welcome and SmithKline Beecham merge at last. http://www.pharmaceuticalonline.com/article.mvc/Glaxo-Wellcome-and-SmithKline-Beecham-Merge-a-0001. Accessed Nov 2017
  7. Pursche WR (1996) Mergers and Acquisitions–Pharmaceuticals –the consolidation isn’t over. Mckinsey Quarterly. No 2Google Scholar
  8. Ravenscraft DJ, Long WF (2000) The paths to creating value in pharmaceutical mergers. http://www.nber.org/chapters/c8653; http://www.nber.org/books/kapl00-1. Mergers and Productivity. University of Chicago Press. National Bureau of Economic Research
  9. Robert Stevens (2000) Glaxo Wellcome SmithKline Beecham merger creates world’s largest drug company. http://www.wsws.org/articles/2000/jan2000/glax-j22.shtml. Accessed 01 Nov 2017

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • B. Rajesh Kumar
    • 1
  1. 1.Institute of Management TechnologyDubaiUnited Arab Emirates

Personalised recommendations